Acarbose could delay onset of type-2 diabetes

June 13, 2002

An international study in this week's issue of THE LANCET suggests that the drug acarbose could be used to delay the development of type-2 diabetes in patients with slightly raised blood sugar (impaired glucose tolerance).

The worldwide increase in type-2 diabetes (the onset of diabetes in middle/old age due to impaired insulin production) is becoming a major health concern. Jean-Louis Chiasson from the University of Montreal, Canada, and colleagues aimed to assess the effect of the drug acarbose in preventing or delaying conversion of impaired glucose tolerance to type-2 diabetes.

Around 1400 patients from Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, and Spain with impaired glucose tolerance were randomly assigned 100 mg acarbose or placebo three times daily. The primary endpoint was the development of diabetes on the basis of a yearly oral glucose tolerance test.

31% of patients given acarbose and 19% of patients given placebo discontinued treatment early. 10% fewer patients given acarbose developed diabetes (32% compared with 42%, respectively)--a relative reduction in risk of 25%. Furthermore, acarbose significantly increased reversion of impaired glucose tolerance to normal glucose tolerance. The main side effects of acarbose were flatulence and diarrhoea.

Jean-Louis Chiasson comments: "Lifestyle modification has already been shown to prevent type-2 diabetes. Our results show that intervention with acarbose is also effective. Whether these two treatment options can be used together remains to be determined. Nevertheless, recommendations for screening and treatment of impaired glucose tolerance should now be reassessed."
Contact: Professor Jean-Louis Chiasson, Research Centre, Centre Hospitalier de l'Université de Montréal, Hôtel-Dieu, 3850 St Urbain Street, Room 8-202, Montreal, Quebec H2W 1T7, Canada; T) +1 514 890 8000x12732; F) +1 514 412 7208; E)


Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to